Emergingby GlyphGenerate Biomedicines prices $400M Nasdaq IPO
Shares priced at $16.00 and trade under the ticker GENB.
Synthetic biologygeneratebiomedicines.com
Generate Biomedicines
Public companyUS1 field
Where it works
| Technology | ||
|---|---|---|
| Synthetic biologyDesigns protein and antibody drugs with generative AI; listed on Nasdaq as GENB. | Designs protein and antibody drugs with generative AI; listed on Nasdaq as GENB. | generatebiomedicines.com |
Events
Generate Biomedicines to start Phase 3 studies of AI-engineered asthma antibody
GB-0895 is a long-acting anti-TSLP antibody for severe asthma.
Synthetic biologygeneratebiomedicines.com
Funding
$400M
About
- Source
- generatebiomedicines.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Sep 25, 2026
Generate Biomedicines
Joined in Synthetic biology. Designs protein and antibody drugs with generative AI; listed on Nasdaq as GENB.
Generate Biomedicines
Added in Synthetic biology. Designs protein and antibody drugs with generative AI; listed on Nasdaq as GENB.